Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Oncolytics Biotech Inc. has received an average rating of "Moderate Buy" from analysts, with one hold rating and three buy ratings among the four firms covering the stock.
• The company's stock price is currently $1.02, with a one-year range between $0.33 and $1.53, and a market capitalization of approximately $96.17 million.
• Oncolytics Biotech reported earnings of ($0.06) per share, exceeding analysts' expectations of ($0.09), and is predicted to post -0.28 EPS for the current year.

Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) has been assigned an average rating of "Moderate Buy" from the four research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $4.33.

ONCY has been the topic of a number of research analyst reports. HC Wainwright reiterated a "buy" rating and issued a $5.00 target price on shares of Oncolytics Biotech in a research note on Wednesday, May 21st. Jones Trading reissued a "hold" rating on shares of Oncolytics Biotech in a research report on Friday, May 16th.

Institutional Trading of Oncolytics Biotech

A hedge fund recently raised its stake in Oncolytics Biotech stock. National Bank of Canada FI grew its holdings in Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) by 199.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 64,479 shares of the company's stock after buying an additional 42,955 shares during the quarter. National Bank of Canada FI owned 0.08% of Oncolytics Biotech worth $60,000 as of its most recent filing with the SEC. 6.82% of the stock is owned by institutional investors and hedge funds.

Oncolytics Biotech Stock Down 2.9%

ONCY stock traded down $0.03 during trading hours on Wednesday, hitting $0.99. The company's stock had a trading volume of 537,614 shares, compared to its average volume of 1,311,766. The company has a market capitalization of $96.44 million, a PE ratio of -3.41 and a beta of 1.09. Oncolytics Biotech has a 12 month low of $0.33 and a 12 month high of $1.53. The stock has a 50 day moving average price of $0.80 and a two-hundred day moving average price of $0.69.

Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.03. Sell-side analysts expect that Oncolytics Biotech will post -0.28 earnings per share for the current year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.